FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver
Executive Summary
FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.
You may also be interested in...
Conflicting Data In Review Of New GnRH Risks
Writers of journal article say enough data exists to warrant more study of increased cardiovascular risks found in prostate cancer patients taking the drugs.
FDA Wants More REMS Authority To Speed Negotiations With Sponsors
FDA would like Congress to provide the agency with a larger role in writing Risk Evaluation and Mitigation Strategies, Principal Deputy Commissioner Joshua Sharfstein indicated during a House Energy and Commerce Health Subcommittee hearing on March 10
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia